Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff Aug 28, 2020). We aimed to assess overall survival based on 7 months of additio...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology Vol. 24; no. 3; pp. 228 - 238
Main Authors: Choueiri, Toni K, Eto, Masatoshi, Motzer, Robert, De Giorgi, Ugo, Buchler, Tomas, Basappa, Naveen S, Méndez-Vidal, María José, Tjulandin, Sergei, Hoon Park, Se, Melichar, Bohuslav, Hutson, Thomas, Alemany, Carlos, McGregor, Bradley, Powles, Thomas, Grünwald, Viktor, Alekseev, Boris, Rha, Sun Young, Kopyltsov, Evgeny, Kapoor, Anil, Alonso Gordoa, Teresa, Goh, Jeffrey C, Staehler, Michael, Merchan, Jaime R, Xie, Ran, Perini, Rodolfo F, Mody, Kalgi, McKenzie, Jodi, Porta, Camillo G
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-03-2023
Elsevier Limited
Subjects:
Antitumor agents
Cancer therapies
Carcinoma, Renal Cell
Consent
Drug dosages
Everolimus
FDA approval
Female
Follow-Up Studies
Hemoglobin
Humans
Immunotherapy
Inhibitor drugs
Kidney cancer
Kidney Neoplasms
Laboratories
Male
Medical prognosis
Middle Aged
Monoclonal antibodies
Patients
Pembrolizumab
Renal cell carcinoma
Response rates
Solid tumors
Sunitinib
Targeted cancer therapy
Vascular endothelial growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff Aug 28, 2020). We aimed to assess overall survival based on 7 months of additional follow-up. This is a protocol-prespecified updated overall survival analysis (data cutoff March 31, 2021) of the open-label, phase 3, randomised CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy for renal cell carcinoma, including anti-vascular endothelial growth factor therapy, or any systemic investigational anticancer drug, were eligible for inclusion from 200 sites (hospitals and cancer centres) across 20 countries. Patients were randomly assigned (1:1:1) to receive lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days; lenvatinib plus pembrolizumab group), lenvatinib (18 mg per day orally) plus everolimus (5 mg per day orally; lenvatinib plus everolimus group [not reported in this updated analysis]) in 21-day cycles, or sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off; sunitinib group). Eligible patients were at least 18 years old with a Karnofsky performance status of 70 or higher. A computer-generated randomisation scheme was used, and stratification factors were geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint was progression-free survival assessed by independent imaging review according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). In this Article, extended follow-up analyses for progression-free survival and protocol-specified updated overall survival data are reported for the intention-to-treat population. No safety analyses were done at this follow-up. This study is closed to new participants and is registered with ClinicalTrials.gov, NCT02811861. Between Oct 13, 2016, and July 24, 2019, 1417 patients were screened for inclusion in the CLEAR trial, of whom 1069 (75%; 273 [26%] female, 796 [74%] male; median age 62 years [IQR 55–69]) were randomly assigned: 355 (33%) patients (255 [72%] male and 100 [28%] female) to the lenvatinib plus pembrolizumab group, 357 (33%) patients (275 [77%] male and 82 [23%] female) to the sunitinib group, and 357 (33%) patients to the lenvatinib plus everolimus group (not reported in this updated analysis). Median follow-up for progression-free survival was 27·8 months (IQR 20·3–33·8) in the lenvatinib plus pembrolizumab group and 19·4 months (5·5–32·5) in the sunitinib group. Median progression-free survival was 23·3 months (95% CI 20·8–27·7) in the lenvatinib plus pembrolizumab group and 9·2 months (6·0–11·0) in the sunitinib group (stratified hazard ratio [HR] 0·42 [95% CI 0·34–0·52]). Median overall survival follow-up was 33·7 months (IQR 27·4–36·9) in the lenvatinib plus pembrolizumab group and 33·4 months (26·7–36·8) in the sunitinib group. Overall survival was improved with lenvatinib plus pembrolizumab (median not reached [95% CI 41·5–not estimable]) versus sunitinib (median not reached [38·4–not estimable]; HR 0·72 [95% CI 0·55–0·93]). Efficacy benefits of lenvatinib plus pembrolizumab over sunitinib were durable and clinically meaningful with extended follow-up. These results support the use of lenvatinib plus pembrolizumab as a first-line therapy for patients with advanced renal cell carcinoma. Eisai and Merck Sharp & Dohme.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(23)00049-9